Business Context and Reporting Period
This Form 8-K Current Report was filed by Polaris Industries Inc. on April 10, 2017. The filing addresses a material modification to the rights of security holders regarding the company's poison pill defense mechanism.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and the termination of a specific rights agreement.
Material Changes
- Expiration Date Change: The Board of Directors approved an amendment to the Amended and Restated Rights Agreement (dated April 29, 2010) to change the final expiration date from April 29, 2020, to April 14, 2017.
- Termination: The Rights Agreement will terminate with no further force and effect at the close of business on April 14, 2017.
- Delisting: The Rights will be de-listed from the New York Stock Exchange and de-registered under the Securities Exchange Act of 1934.
Management Commentary and Rationale
The amendment was approved as part of the Board's ongoing review of corporate governance practices and in response to input from shareholders on this topic. The company intends to remove the poison pill provision entirely rather than extending it.
Investor Verification Checklist
- Confirm the Rights Agreement is officially terminated as of the close of business on April 14, 2017.
- Verify the de-listing of the Rights from the New York Stock Exchange.
- Review the attached Exhibit 4.1 for the full legal text of the Amendment to the Rights Agreement.